Literature DB >> 32606347

Distinct stem/progenitor cells proliferate to regenerate the trachea, intrapulmonary airways and alveoli in COVID-19 patients.

Yinshan Fang1, Helu Liu1, Huachao Huang1, Haiyan Li2, Anjali Saqi3, Li Qiang3, Jianwen Que4.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32606347      PMCID: PMC7325636          DOI: 10.1038/s41422-020-0367-9

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


× No keyword cloud information.
Dear Editor, The global pandemic COVID-19 caused by SARS-CoV-2 virus has infected over 6.5 million individuals and claimed over 350,000 lives worldwide within six months. The respiratory epithelial cells covering the airways and alveoli are the major targets of the virus. Moreover, damage to the epithelium can be exacerbated by mechanical ventilation. It is expected that many of the infected individuals that survived the acute phase will develop pulmonary diseases (e.g. fibrosis) if the epithelium fails to regenerate properly. Multiple stem/progenitor cells have been implicated in the regeneration of the respiratory epithelium. The human trachea and intrapulmonary airways are lined by three major cell types, basal, club and ciliated cells, and the alveolar epithelium includes type 1 (AT1) and type 2 (AT2) cells. The trachea basal cells have been shown to serve as progenitor cells to self-renew and differentiate into other cell types including club, ciliated cells and minor cell populations (e.g., tuft cells).[1,2] Club cells can also de-differentiate into basal cells to regenerate the tracheal epithelium in a mouse model where basal cells are ablated prior to injury.[3] In the intrapulmonary airways, basal cells have been postulated to serve as progenitor cells for epithelial regeneration in humans (reviewed by[4]). In mice, however, club cells are responsible for repopulating the intrapulmonary airway epithelium upon injury due to their lack of basal cells in the intrapulmonary airways.[5] The cell of origin for regenerating the alveolar epithelium remains controversial. Multiple cell types have been implicated in the regeneration of the alveolar epithelium depending on injury models. These cells include AT1 and AT2 cells, bronchial-alveolar ductal cells (BASCs), distal airway stem cells (DASCs), lineage negative epithelial precursor (LNEP) cells, bronchial epithelial stem cells (BESCs), and different AT2 subpopulation cells (reviewed by[6]). Although histology analysis has been performed, it remains unknown which stem/progenitor cell(s) proliferate in response to viral challenges in COVID-19 patients. Cellular entry of SARS-CoV-2 depends on the extracellular receptor Angiotensin Converting Enzyme 2 (ACE2) and the serine protease transmembrane serine protease 2 (TMPRSS2). ACE2 and TMPRSS2 are expressed in both nasal and bronchial epithelium as detected by immunohistochemistry.[7] Single cell RNA-sequencing analysis confirmed that ACE2 is enriched in the human airway epithelium including club, ciliated and goblet cells, AT1 and AT2 cells.[8,9] ACE2 and TMPRSS2 are also co-expressed in a subpopulation of ciliated cells and AT2 cells.[8] Consistently, histology characterization revealed that SARS-CoV-2 infection induces severe damages in the intrapulmonary airways and alveoli.[10] However, detailed characterization of different respiratory cell types remains lacking for COVID-19 patients. In this report we showed that ciliated, club, AT1 and AT2 cells are the major cell types damaged by SARS-CoV-2 infection. More importantly, we demonstrated that distinct proliferating cells are present in the trachea/large airways, small airways and alveoli following SARS-CoV-2 infection. We examined tracheas and lungs from five deceased patients with postmortem intervals (PMIs) as low as 2.5 hours. The epithelium was severely damaged in some parts of the trachea (Supplementary information, Fig. S1a, b). Ciliated and club cells were shed into the lumen, and the underlying basal cells were exposed (Fig. 1a, b and data not shown). Although KRT5 remained to be expressed in these exposed basal cells, the nuclei rounded up in contrast to the neighboring basal cells where the overlaying club and ciliated were intact (Supplementary information, Fig. S1c). Intriguingly, although basal cells and other epithelial cells rarely proliferate at homeostasis in the adults,[1] extensive basal cell proliferation was observed in the trachea, especially in the area where club and ciliated cells were damaged (Fig. 1b). The proliferating cells were limited to the immediate parabasal layer in the area where the epithelial integrity was relatively well maintained (Fig. 1a). However, in the severely damaged area, proliferating cells were occasionally observed in the basal layer which is lined by basal cells with round nuclei (Fig. 1b). Together these findings demonstrate that in the trachea basal cells proliferate, likely serving as progenitor cells to regenerate the damaged epithelium following SARS-CoV-2 infection.
Fig. 1

Distinct proliferating cells in the trachea, intrapulmonary airways and alveoli of COVID-19 patients.

a Proliferating basal cells are enriched in the area where severe damages occur. Note Ki67+ cells are limited to the immediate parabasal layer. b Proliferating basal cells are present in the basal (arrowheads) and immediate parabasal layers where the overlaying club and ciliated are depleted. c Proliferating cells in the intrapulmonary airways include basal cells (arrowheads), club cells (long arrows) and KRT5− SCGB1A1− population (arrows). d Extensive proliferating alveolar type 2 cells (arrows). e Schematics of proliferating epithelial cells in COVID-19 trachea and lung. Note the predominant proliferating cells in the small airways are Lineage Negative Proliferating Cells (LNPCs). In this study tracheas and lungs from five COVID-19 patients were examined. Scale bar, 50 µm.

Distinct proliferating cells in the trachea, intrapulmonary airways and alveoli of COVID-19 patients.

a Proliferating basal cells are enriched in the area where severe damages occur. Note Ki67+ cells are limited to the immediate parabasal layer. b Proliferating basal cells are present in the basal (arrowheads) and immediate parabasal layers where the overlaying club and ciliated are depleted. c Proliferating cells in the intrapulmonary airways include basal cells (arrowheads), club cells (long arrows) and KRT5SCGB1A1− population (arrows). d Extensive proliferating alveolar type 2 cells (arrows). e Schematics of proliferating epithelial cells in COVID-19 trachea and lung. Note the predominant proliferating cells in the small airways are Lineage Negative Proliferating Cells (LNPCs). In this study tracheas and lungs from five COVID-19 patients were examined. Scale bar, 50 µm. We next examined the COVID-19 lungs. The intrapulmonary airways and alveoli were severely damaged with epithelial denudation and extensive intra-alveolar fibrinous exudates (Supplementary information, Fig. S2a). A significant amount of ciliated and club cells were sloughed and detached from basal cells in some areas (Supplementary information, Fig. S2b). In the large airways (diameter > 0.5 mm), 82% of Ki67+ cells co-express KRT5 (Supplementary information, Fig. S3a), suggesting that basal cell remains to be the major proliferative cell population in response to viral challenge. By contrast, in the small airways (diameter < 0.5 mm) although 29.08% ± 2.93% of basal cells showed Ki67 expression, the majority of proliferating epithelial cells were KRT5− (4.10% ± 1.53% SCGB1A1+ KRT5− and 66.82% ± 3.31% SCGB1A1KRT5−). Goblet cells (MUC5AC+) and ciliated cells (FOXJ1+) were not proliferative (Supplementary information, Fig. S3a and data not shown, n = 5). Although a previous study showed that approximately 1% to 2% of neuroendocrine cells are proliferative,[11] we did not observe any Ki67+ neuroendocrine cells (Synaptophysin, SYP+) (Supplementary information, Fig. S3b, 0/16 cells). While extensive CD45+ cells were present in the mesenchyme, the inflammatory cells did not seem to infiltrate into the epithelial layer (Supplementary information, Fig. S3c). We did not observe proliferating AT1 cells in the alveoli (Supplementary information, Fig. S4). 3.99% ± 1.66% of AT2 cells exhibited Ki67 staining in the parenchyma where the alveoli were relatively well preserved. However, in severely damaged area 15.69% ± 1.87% of AT2 cells were proliferative (Fig. 1d; Supplementary information, Fig. S4), suggesting that AT2 cells are mobilized to regenerate the alveoli. Taken together, we demonstrate that distinct cell populations proliferate in different regions of the respiratory system following SARS-CoV-2 infection (Fig. 1e). In the trachea and larger airways basal cells (KRT5+) proliferate extensively. This is consistent with a previous report showing that approximately 84% proliferating cells express KRT5 in the normal large airways (>2 mm).[12] Interestingly, although approximately 30% proliferating cells exhibit KRT5 expression in the small airways of COVID-19 lungs, the majority of proliferating cells do not express KRT5. Among them the predominant cell population does not express lineage markers including SCGB1A1, FOXJ1, acetylated tubulin, MUC5AC and SYP as evidenced by immunostaining. Whether these Lineage Negative Proliferating Cells (LNPCs) are similar to the LNEPs identified in mouse models[13] remains to be determined. It is also unknown whether these cells are derived from the underlying basal cells or neighboring club cells. The alveoli AT2 cells proliferate extensively in response to virus-induced damage. Mouse studies have shown that basal cells and AT2 cells consist of multiple subpopulations (reviewed by[6]). It will be interesting to further determine which subpopulations are activated and participate in lung regeneration in COVID-19 patients. Understanding the molecular mechanisms that promote the expansion of distinct progenitors present in the proximal/distal airways and alveoli is critical for rebuilding a functional respirator system. Supplementary, Figures and Methods
  20 in total

1.  Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19.

Authors:  Ji Hoon Ahn; JungMo Kim; Seon Pyo Hong; Sung Yong Choi; Myung Jin Yang; Young Seok Ju; Young Tae Kim; Ho Min Kim; M D Tazikur Rahman; Man Ki Chung; Sang Duk Hong; Hosung Bae; Chang-Seop Lee; Gou Young Koh
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

2.  Disruption of respiratory epithelial basement membrane in COVID-19 patients.

Authors:  Xue Liu; Yinshan Fang; Paul W Noble; Jianwen Que; Dianhua Jiang
Journal:  Mol Biomed       Date:  2021-03-20

3.  Epithelial Wntless regulates postnatal alveologenesis.

Authors:  Yinshan Fang; Hongxia Shao; Qi Wu; Neng Chun Wong; Natalie Tsong; Patricia J Sime; Jianwen Que
Journal:  Development       Date:  2022-01-10       Impact factor: 6.868

4.  Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial.

Authors:  Najmeh Kaffash Farkhad; Alireza Sedaghat; Hamidreza Reihani; Amir Adhami Moghadam; Ahmad Bagheri Moghadam; Nayereh Khadem Ghaebi; Mohammad Ali Khodadoust; Rashin Ganjali; Amir Reza Tafreshian; Jalil Tavakol-Afshari
Journal:  Stem Cell Res Ther       Date:  2022-06-28       Impact factor: 8.079

5.  VEGF receptor 2 (KDR) protects airways from mucus metaplasia through a Sox9-dependent pathway.

Authors:  Ming Jiang; Yinshan Fang; Yu Li; Huachao Huang; Zichen Wei; Xia Gao; Hoon-Ki Sung; Jim Hu; Li Qiang; Jian Ruan; Qixuan Chen; Dianhua Jiang; Jeffrey A Whitsett; Xingbin Ai; Jianwen Que
Journal:  Dev Cell       Date:  2021-05-18       Impact factor: 13.417

6.  Impaired lung regeneration after SARS-CoV-2 infection.

Authors:  Hongxia Shao; Zhonghua Qin; Bei Geng; Junping Wu; Lixia Zhang; Qiuyang Zhang; Qi Wu; Li Li; Huaiyong Chen
Journal:  Cell Prolif       Date:  2020-10-20       Impact factor: 6.831

7.  Basal epithelial stem cells cross an alarmin checkpoint for postviral lung disease.

Authors:  Kangyun Wu; Kenji Kamimoto; Yong Zhang; Kuangying Yang; Shamus P Keeler; Benjamin J Gerovac; Eugene V Agapov; Stephen P Austin; Jennifer Yantis; Kelly A Gissy; Derek E Byers; Jennifer Alexander-Brett; Christy M Hoffmann; Matthew Wallace; Michael E Hughes; Erika C Crouch; Samantha A Morris; Michael J Holtzman
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 14.808

Review 8.  The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection.

Authors:  Oreste Gallo; Luca Giovanni Locatello; Alessio Mazzoni; Luca Novelli; Francesco Annunziato
Journal:  Mucosal Immunol       Date:  2020-11-26       Impact factor: 7.313

9.  Long-Term Modeling of SARS-CoV-2 Infection of In Vitro Cultured Polarized Human Airway Epithelium.

Authors:  Siyuan Hao; Kang Ning; Cagla Aksu Kuz; Kai Vorhies; Ziying Yan; Jianming Qiu
Journal:  mBio       Date:  2020-11-06       Impact factor: 7.867

Review 10.  First contact: the role of respiratory cilia in host-pathogen interactions in the airways.

Authors:  Li Eon Kuek; Robert J Lee
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-12       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.